Company profile
Amarantus BioScience Holdings, Inc.
OTC: AMBS · Healthcare · Biotechnology
#945 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 4GM —SS 38
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), listing tenure · ↓ disclosure history, filing timeliness
Methodology →Revenue TTM
$96.6k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$25.2M
Employees
12
as of 2026-08-29
Market cap
$36.8k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$416.0k$416.0k2012
Net income-$25.2M-$25.2M2015
Operating income-$24.8M-$24.8M2015
Total assets$11.8M$11.8M2015
Liabilities$17.3M$17.3M2015
Equity-$8.7M-$8.7M2015
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Amarantus BioScience Holdings, Inc.’s revenue?
Amarantus BioScience Holdings, Inc. booked $416.0k in FY2012 revenue, growing 86% year over year — faster than most Healthcare companies we track, at a -6061.1% net margin.
Peers · Healthcare
Scienture Holdings, Inc.50DNiki BioSolutions, Inc.31DAequus Pharmaceuticals Inc.——MediciNova, Inc.41DCartesian Therapeutics, Inc.40DiBio, Inc.48DNeighbors
New York →Key facts
CEOJohn Wesley Commissiong
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeOTC: AMBS
Employees12
IPO date2010-09-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.